Evolus says its Botox biosimilar could be delayed by FDA issues with Daewoong plant
admin 25th January 2018 Uncategorised 0Some Allergan investors have felt queasy about the potential for Botox knockoffs to suck up some of the company’s bottom line. But manufacturing issues for one of those players, Evolus, could delay approval of its candidate.
More: Evolus says its Botox biosimilar could be delayed by FDA issues with Daewoong plant
Source: fierce